Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Oruka Therapeutics, Inc.’s reported figures.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
FAQ
- What is Oruka Therapeutics, Inc.'s EBITDA?
- Oruka Therapeutics, Inc. (ORKA) reported EBITDA of -$36.39M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s EBITDA changed year-over-year?
- Oruka Therapeutics, Inc.'s EBITDA decreased by 45.2% year-over-year, from -$25.07M to -$36.39M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s EBITDA has grown at a 58.5% compound annual growth rate (CAGR), from -$19.32M to -$121.97M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Oruka Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude